Literature DB >> 22974762

Iron chelation inhibits the development of pulmonary vascular remodeling.

Chi-Ming Wong1, Ioana R Preston, Nicholas S Hill, Yuichiro J Suzuki.   

Abstract

Reactive oxygen species (ROS) have been implicated in the pathogenesis of pulmonary hypertension. Because iron is an important regulator of ROS biology, this study examined the effects of iron chelation on the development of pulmonary vascular remodeling. The administration of an iron chelator, deferoxamine, to rats prevented chronic hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling. Various iron chelators inhibited the growth of cultured pulmonary artery smooth muscle cells. Protein carbonylation, an important iron-dependent biological event, was promoted in association with pulmonary vascular remodeling and cell growth. A proteomic approach identified that Rho GDP-dissociation inhibitor (a negative regulator of RhoA) is carbonylated. In human plasma, the protein carbonyl content was significantly higher in patients with idiopathic pulmonary arterial hypertension than in healthy controls. These results suggest that iron plays an important role in the ROS-dependent mechanism underlying the development of pulmonary hypertension.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22974762      PMCID: PMC3472156          DOI: 10.1016/j.freeradbiomed.2012.08.576

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  46 in total

Review 1.  Protein oxidation.

Authors:  E R Stadtman; R L Levine
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

Review 2.  Determination of carbonyl groups in oxidized proteins.

Authors:  R L Levine; N Wehr; J A Williams; E R Stadtman; E Shacter
Journal:  Methods Mol Biol       Date:  2000

3.  Superoxide as an intermediate signal for serotonin-induced mitogenesis.

Authors:  S L Lee; W W Wang; B L Fanburg
Journal:  Free Radic Biol Med       Date:  1998-03-15       Impact factor: 7.376

4.  Increased oxidative stress in lambs with increased pulmonary blood flow and pulmonary hypertension: role of NADPH oxidase and endothelial NO synthase.

Authors:  Albert C Grobe; Sandra M Wells; Eileen Benavidez; Peter Oishi; Anthony Azakie; Jeffrey R Fineman; Stephen M Black
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2006-06       Impact factor: 5.464

5.  Hypoxic pulmonary hypertension: role of superoxide and NADPH oxidase (gp91phox).

Authors:  John Q Liu; Igor N Zelko; Efua M Erbynn; James S K Sham; Rodney J Folz
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2005-08-05       Impact factor: 5.464

6.  Effects of desferrioxamine on serum erythropoietin and ventilatory sensitivity to hypoxia in humans.

Authors:  X Ren; K L Dorrington; P H Maxwell; P A Robbins
Journal:  J Appl Physiol (1985)       Date:  2000-08

7.  Retinoids and pulmonary hypertension.

Authors:  Ioana R Preston; Guangwen Tang; Jason U Tilan; Nicholas S Hill; Yuichiro J Suzuki
Journal:  Circulation       Date:  2005-02-07       Impact factor: 29.690

Review 8.  Oxidants as stimulators of signal transduction.

Authors:  Y J Suzuki; H J Forman; A Sevanian
Journal:  Free Radic Biol Med       Date:  1997       Impact factor: 7.376

9.  Requirement for generation of H2O2 for platelet-derived growth factor signal transduction.

Authors:  M Sundaresan; Z X Yu; V J Ferrans; K Irani; T Finkel
Journal:  Science       Date:  1995-10-13       Impact factor: 47.728

10.  Glutamic and aminoadipic semialdehydes are the main carbonyl products of metal-catalyzed oxidation of proteins.

Authors:  J R Requena; C C Chao; R L Levine; E R Stadtman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

View more
  17 in total

1.  Reactive Oxygen Species, Biomarkers of Microvascular Maturation and Alveolarization, and Antioxidants in Oxidative Lung Injury.

Authors:  Arwin M Valencia; Maria A Abrantes; Jamal Hasan; Jacob V Aranda; Kay D Beharry
Journal:  React Oxyg Species (Apex)       Date:  2018-11

2.  IL-22 activates oxidant signaling in pulmonary vascular smooth muscle cells.

Authors:  Geetanjali Bansal; Dividutta Das; Cheng-Ying Hsieh; Yi-Hsuan Wang; Brent A Gilmore; Chi-Ming Wong; Yuichiro J Suzuki
Journal:  Cell Signal       Date:  2013-09-07       Impact factor: 4.315

Review 3.  Role of reactive oxygen species in neonatal pulmonary vascular disease.

Authors:  Stephen Wedgwood; Robin H Steinhorn
Journal:  Antioxid Redox Signal       Date:  2014-02-19       Impact factor: 8.401

Review 4.  Underappreciated roles for Rho GDP dissociation inhibitors (RhoGDIs) in cell function: Lessons learned from the pancreatic islet β-cell.

Authors:  Anjaneyulu Kowluru; Noah F Gleason
Journal:  Biochem Pharmacol       Date:  2021-12-28       Impact factor: 5.858

5.  Endothelin-1 depletion of cartilage oligomeric matrix protein modulates pulmonary artery superoxide and iron metabolism-associated mitochondrial heme biosynthesis.

Authors:  Hang Yu; Norah Alruwaili; Melissa R Kelly; Bin Zhang; Aijing Liu; Yingqi Wang; Dong Sun; Michael S Wolin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2022-08-09       Impact factor: 6.011

Review 6.  Multifaceted Roles of Ferroptosis in Lung Diseases.

Authors:  Yi Li; Ying Yang; Yongfeng Yang
Journal:  Front Mol Biosci       Date:  2022-06-24

Review 7.  Atherogenesis and iron: from epidemiology to cellular level.

Authors:  Francesca Vinchi; Martina U Muckenthaler; Milene C Da Silva; György Balla; József Balla; Viktória Jeney
Journal:  Front Pharmacol       Date:  2014-05-05       Impact factor: 5.810

Review 8.  Hematological disorders and pulmonary hypertension.

Authors:  Rajamma Mathew; Jing Huang; Joseph M Wu; John T Fallon; Michael H Gewitz
Journal:  World J Cardiol       Date:  2016-12-26

9.  Iron deficiency in pulmonary arterial hypertension: perspectives.

Authors:  Marceau Quatredeniers; David Montani; Alain Cohen-Solal; Frédéric Perros
Journal:  Pulm Circ       Date:  2021-06-14       Impact factor: 3.017

10.  Supplementation of iron in pulmonary hypertension: Rationale and design of a phase II clinical trial in idiopathic pulmonary arterial hypertension.

Authors:  Luke S G E Howard; Geoffrey M J Watson; John Wharton; Christopher J Rhodes; Kakit Chan; Rajeshree Khengar; Peter A Robbins; David G Kiely; Robin Condliffe; Charlie A Elliott; Joanna Pepke-Zaba; Karen Sheares; Nicholas W Morrell; Rachel Davies; Deborah Ashby; J Simon R Gibbs; Martin R Wilkins
Journal:  Pulm Circ       Date:  2013-01       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.